Clinical Trials Directory

Trials / Unknown

UnknownNCT04121013

PREhospital Routage of Acute STroke Patients With Suspected Large Vessel Occlusion: Mothership Versus Drip and Ship

PREhospital Routage of Acute STroke Patients With Suspected Large Vessel Occlusion: Mothership Versus Drip and Ship, a Randomized Control Study in France (PRESTO-F)

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
800 (estimated)
Sponsor
University Hospital, Caen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Background: The outcome of ischemic stroke is related to the brain lesion volume and this volume of infarction is directly related to the time to reperfusion, which therefore depends on the time to initiation of therapy. Acute ischemic stroke is treated medically with the administration of intravenous rtPA, but recent randomized controlled trials have shown the efficacy of mechanical thrombectomy and is now the new gold standard in ischemic stroke. This new therapeutic strategy has created two possibilities for pre-hospital decision-making: i/ transport the patient directly to the nearest stroke unit to receive alteplase and then if indicated perform a thrombectomy (drip and ship) or ii/ bypassing thrombolysis centres in favour of endovascular thrombectomy (mothership). Objective: To compare cost/effectiveness of transfer to the closest local stroke centre or telemedicine hub to direct transfer to the comprehensive stroke cent(CSC) in patients acute stroke with suspected large vessel occlusion. Medical and economic expected impact: We hypothesize that direct transportation to CSC is associated with better clinical outcome in case of acute ischaemic stroke due to intracranial large vessel occlusion. However, we have to demonstrate that this approach is not associated with time from onset harm in patients not eligible to mechanical thrombectomy.

Detailed description

Design: Multicenter, two-arm, prospective, open, blinded end-point (PROBE), randomized, clinical trial Primary endpoint: Incremental cost-utility ratio at 12 months. Secondary endpoints: modified Rankin scale and EuroQoL5D scale at 3 months. Eligibility criteria: A call to the emergency medical assistance service, 18 years and older, severe acute stroke symptoms, transportation time from scene to the CSC longer than time to go to the nearest stroke unit or telemedicine hub, transportation time from scene to the CSC compatible with IV thrombolysis, known time from onset, RACE score (assessed by medical emergency technicians) ≥5. Experimental arm: direct transportation to the CSC. Control arm: transfer to the closest local stroke centre or telemedicine hub. Sample size: 800 patients, 400 for each arm.

Conditions

Interventions

TypeNameDescription
OTHERmothershipRandomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence

Timeline

Start date
2021-01-30
Primary completion
2022-01-01
Completion
2022-01-01
First posted
2019-10-09
Last updated
2021-04-14

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04121013. Inclusion in this directory is not an endorsement.